Cargando…

Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma

The patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) have poor prognosis, and a novel and effective therapeutic strategy for these patients is urgently needed. Although ubiquitin-specific protease 1 (USP1) plays a key role in cancer, the carcinogenic effect of USP1 in B-ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xi-Ya, Wu, Ji-Chuan, Liu, Ping, Li, Zi-Juan, Wang, Yong, Chen, Bing-Yi, Hu, Cheng-Long, Fei, Ming-Yue, Yu, Peng-Cheng, Jiang, Yi-Lun, Xu, Chun-Hui, Chang, Bin-He, Chen, Xin-Chi, Zong, Li-Juan, Zhang, Jia-Ying, Fang, Ying, Sun, Xiao-Jian, Xue, Kai, Wang, Li, Chen, Shu-Bei, Jiang, Shi-Yu, Gui, Ai-ling, Yang, Ling, Gu, Juan J., Yu, Bao-Hua, Zhang, Qun-ling, Wang, Lan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883169/ https://www.ncbi.nlm.nih.gov/pubmed/36352191 http://dx.doi.org/10.1038/s41375-022-01747-2

Ejemplares similares

USP9X destabilizes pVHL and promotes cell proliferation
por: Zhang, Cong, et al.
Publicado: (2016)

USP1 inhibition suppresses the progression of osteosarcoma via destabilizing TAZ
por: Yuan, Putao, et al.
Publicado: (2022)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
por: Li, Xin, et al.
Publicado: (2018)

Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma
por: Xue, Kai, et al.
Publicado: (2021)

P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Zhang, Xiyuan, et al.
Publicado: (2023)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022)

Max deletion destabilizes MYC protein and abrogates Eµ-Myc lymphomagenesis
por: Mathsyaraja, Haritha, et al.
Publicado: (2019)

CAG regimen for refractory or relapsed adult T‐cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study
por: Qian, Jie‐Jing, et al.
Publicado: (2020)

Substrate-specific recognition of IKKs mediated by USP16 facilitates autoimmune inflammation
por: Yu, Jian-shuai, et al.
Publicado: (2021)

Hypoxia-induced circWSB1 promotes breast cancer progression through destabilizing p53 by interacting with USP10
por: Yang, Rui, et al.
Publicado: (2022)

Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma
por: Wang, Shu-Bei, et al.
Publicado: (2019)

Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China
por: Liu, Xiangli, et al.
Publicado: (2019)

Elevated Tristetraprolin Impairs Trophoblast Invasion in Women with Recurrent Miscarriage by Destabilization of HOTAIR
por: Tian, Fu-Ju, et al.
Publicado: (2018)

ESE1 expression correlates with neuronal apoptosis in the hippocampus after cerebral ischemia/reperfusion injury
por: Yu, Hai-Long, et al.
Publicado: (2019)

A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL
por: Han, Bo-Wei, et al.
Publicado: (2011)

Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study
por: Wang, Songmi, et al.
Publicado: (2023)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

PIAS3 induction of PRB sumoylation represses PRB transactivation by destabilizing its retention in the nucleus
por: Man, Jiang-Hong, et al.
Publicado: (2006)

Retraction Notice to: Elevated Tristetraprolin Impairs Trophoblast Invasion in Women with Recurrent Miscarriage by Destabilization of HOTAIR
por: Tian, Fu-Ju, et al.
Publicado: (2022)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
por: Wang, Juan, et al.
Publicado: (2021)

Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy
por: Wang, Xue, et al.
Publicado: (2022)

DAB2IP suppresses invadopodia formation through destabilizing ALK by interacting with USP10 in breast cancer
por: Huang, Qingwen, et al.
Publicado: (2023)

Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re‐induction chemotherapy
por: Ruan, Min, et al.
Publicado: (2021)

Trim25 restricts rabies virus replication by destabilizing phosphoprotein
por: Yuan, Yueming, et al.
Publicado: (2022)

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
por: Kong, Xiaoshuang, et al.
Publicado: (2023)

Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase
por: Zheng, Xingnan, et al.
Publicado: (2014)

Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
por: Ren, Liangliang, et al.
Publicado: (2021)

Suppression of Cancer Cell Stemness and Drug Resistance via MYC Destabilization by Deubiquitinase USP45 Inhibition with a Natural Small Molecule
por: Tu, Xiao, et al.
Publicado: (2023)

The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients
por: Jiang, Xuejie, et al.
Publicado: (2015)

Genome-wide analysis and expression profiling under heat and drought treatments of HSP70 gene family in soybean (Glycine max L.)
por: Zhang, Ling, et al.
Publicado: (2015)

Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review
por: Liu, Jing-di, et al.
Publicado: (2016)

USP7 facilitates SMAD3 autoregulation to repress cancer progression in p53-deficient lung cancer
por: Huang, Yu-Ting, et al.
Publicado: (2021)

Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
por: Zhao, Wan-Hong, et al.
Publicado: (2022)

Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation
por: Yang, Chen-lu, et al.
Publicado: (2021)

Single-Cell Transcriptomes Combining with Consecutive Genomics Reveal Clonal Evolution and Gene Regulatory Networks in Relapsed and Refractory Multiple Myeloma
por: Xu, Jiadai, et al.
Publicado: (2022)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study
por: Sun, Feifei, et al.
Publicado: (2020)

Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma
por: Wang, Di, et al.
Publicado: (2018)

Down-regulation of USP13 mediates phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis
por: Geng, Jing, et al.
Publicado: (2015)

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
por: Zhang, Ying, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_44ughc8bfuai4ack25rk57h6hb